Archive | Clinical Trials

Combination of Nivolumab and Ipilimumab Improved Overall Survival For Advanced Melanoma Patients

?WASHINGTON — Among patients with advanced melanoma, those who received both nivolumab (Opdivo) and ipilimumab (Yervoy) had improved overall survival compared with those who received only ipilimumab and appeared to have more favorable survival outcomes compared with those who received nivolumab, according to results from the phase III CheckMate 067 clinical trial presented here at […]

Read the full story

Posted in Melanoma In The News, Clinical Trials

IDO Inhibitor Increases Pembrolizumab Response in Melanoma

Adding the IDO inhibitor indoximod to pembrolizumab (Keytruda) led to an overall response rate (ORR) of 52% in patients with advanced melanoma, according to findings from a phase II trial reported at the 2017 AACR Annual Meeting.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Common Cold Virus Improves Response with Immunotherapy in Advanced Melanoma

Half of patients with advanced melanoma responded to a novel combination treatment consisting of the common cold virus with an immune checkpoint inhibitor, in a recent phase Ib clinical trial presented April 4 at the American Association for Cancer Research (AACR) Annual Meeting.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Adding Coxsackievirus to Ipilimumab Displays Durable Antitumor Activity in Advanced Melanoma

Adding a formulation of the Coxsackievirus A21 (CVA21; CAVATAK®) to ipilimumab (Yervoy) yielded an overall response rate (ORR) of 50% and was well-tolerated in immunotherapy-naïve and pretreated patients with advanced melanoma.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories